CAH vs. RPRX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CAH and RPRX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CAH | RPRX |
|---|---|---|
| Company Name | Cardinal Health, Inc. | Royalty Pharma plc |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Pharmaceuticals |
| Market Capitalization | 37.52 billion USD | 20.43 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | August 4, 1983 | June 16, 2020 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CAH and RPRX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CAH | RPRX |
|---|---|---|
| 5-Day Price Return | 1.54% | -1.37% |
| 13-Week Price Return | -6.57% | -2.08% |
| 26-Week Price Return | 17.15% | 11.79% |
| 52-Week Price Return | 42.96% | 25.06% |
| Month-to-Date Return | 5.50% | -1.95% |
| Year-to-Date Return | 32.71% | 38.30% |
| 10-Day Avg. Volume | 2.68M | 7.23M |
| 3-Month Avg. Volume | 2.26M | 4.24M |
| 3-Month Volatility | 26.45% | 20.41% |
| Beta | 0.72 | 0.55 |
Profitability
Return on Equity (TTM)
CAH
37.17%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
CAH’s Return on Equity of 37.17% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
RPRX
15.20%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
RPRX’s Return on Equity of 15.20% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
CAH
0.70%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
Falling into the lower quartile for the Health Care Providers & Services industry, CAH’s Net Profit Margin of 0.70% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
RPRX
44.28%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
RPRX’s Net Profit Margin of 44.28% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin (TTM)
CAH
1.02%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
CAH’s Operating Profit Margin of 1.02% is in the lower quartile for the Health Care Providers & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
RPRX
79.84%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
RPRX’s Operating Profit Margin of 79.84% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | CAH | RPRX |
|---|---|---|
| Return on Equity (TTM) | 37.17% | 15.20% |
| Return on Assets (TTM) | 3.23% | 5.66% |
| Net Profit Margin (TTM) | 0.70% | 44.28% |
| Operating Profit Margin (TTM) | 1.02% | 79.84% |
| Gross Profit Margin (TTM) | 3.67% | -- |
Financial Strength
Current Ratio (MRQ)
CAH
0.94
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
CAH’s Current Ratio of 0.94 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
RPRX
1.26
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
RPRX’s Current Ratio of 1.26 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
CAH
5.65
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
With a Debt-to-Equity Ratio of 5.65, CAH operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
RPRX
1.26
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
RPRX’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.26. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
CAH
10.77
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
CAH’s Interest Coverage Ratio of 10.77 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
RPRX
4.70
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
RPRX’s Interest Coverage Ratio of 4.70 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | CAH | RPRX |
|---|---|---|
| Current Ratio (MRQ) | 0.94 | 1.26 |
| Quick Ratio (MRQ) | 0.44 | 1.26 |
| Debt-to-Equity Ratio (MRQ) | 5.65 | 1.26 |
| Interest Coverage Ratio (TTM) | 10.77 | 4.70 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CAH
1.31%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
CAH’s Dividend Yield of 1.31% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
RPRX
1.77%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
RPRX’s Dividend Yield of 1.77% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
CAH
31.65%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
CAH’s Dividend Payout Ratio of 31.65% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
RPRX
36.87%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
RPRX’s Dividend Payout Ratio of 36.87% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | CAH | RPRX |
|---|---|---|
| Dividend Yield (TTM) | 1.31% | 1.77% |
| Dividend Payout Ratio (TTM) | 31.65% | 36.87% |
Valuation
Price-to-Earnings Ratio (TTM)
CAH
24.19
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
CAH’s P/E Ratio of 24.19 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
RPRX
20.78
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
RPRX’s P/E Ratio of 20.78 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
CAH
0.17
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
In the lower quartile for the Health Care Providers & Services industry, CAH’s P/S Ratio of 0.17 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
RPRX
9.20
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
With a P/S Ratio of 9.20, RPRX trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
CAH
14.54
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
At 14.54, CAH’s P/B Ratio is at an extreme premium to the Health Care Providers & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
RPRX
3.19
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
RPRX’s P/B Ratio of 3.19 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | CAH | RPRX |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 24.19 | 20.78 |
| Price-to-Sales Ratio (TTM) | 0.17 | 9.20 |
| Price-to-Book Ratio (MRQ) | 14.54 | 3.19 |
| Price-to-Free Cash Flow Ratio (TTM) | 9.24 | 17.62 |